FUTURE PLANS

For a detailed description of our future plans, see "Business—Our Strategies."

USE OF PROCEEDS

Assuming an [**REDACTED**] of HK$[**REDACTED**] per [**REDACTED**] (being the midpoint of the range of the [**REDACTED**] stated in this document), we estimate that we will receive net proceeds of approximately HK$[**REDACTED**] million from the [**REDACTED**] after deducting the [**REDACTED**] commissions and other estimated expenses in connection with the [**REDACTED**] (assuming the [**REDACTED**] is not exercised). We intend to use our proceeds for the purposes and in the amounts set forth below.

(i) Approximately [30.0]%, or HK$[**REDACTED**] million, will be allocated to capacity expansion and facility upgrades. According to Frost & Sullivan, despite recent stagnation, the global and China nonclinical service markets are expected to resume robust growth in the medium to long term, reaching US$37.6 billion and US$7.2 billion, respectively, by 2035. This growth is driven by a number of key factors, including the continued globalization of clinical trials and expansion of emerging markets, increasingly stringent regulatory requirements that stimulate demand for high-quality nonclinical studies and the rapid advancement of innovative therapies and enabling technologies. Taking into consideration the anticipated recovery and long-term growth of the global and China's nonclinical CRO service markets and the relatively high utilization rates of our current facilities (see "—Our Facilities—Our Existing Facilities"), we plan to expand our Nanjing facility and establish a new laboratory facility to enhance our nonclinical service capabilities and support our future development. As of the Latest Practicable Date, such facility was in pilot operation. We plan to undertake the following steps to facilitate its full operation.

   (a) Approximately [5.0]%, or HK$[**REDACTED**] million, will be used to recruit around 350 qualified professionals (with approximately 100 to 120 new hires in each of 2026, 2027 and 2028, and future recruitment timeline to be adjusted according to business needs) for a variety of related positions, such as nonclinical studies researchers, laboratory technicians, analysts, facility support staff, veterinarians and QA specialists, strengthening our scientific and technical expertise.

   (b) Approximately [13.0]%, or HK$[**REDACTED**] million, will be used for the procurement of advanced equipment and upgrading laboratory facilities. Specifically, approximately [11.0]%, or HK$[**REDACTED**] million, would be used for the procurement and upgrade of animal housing and husbandry equipment (such as cages and associated devices required for animal care) and GLP laboratory facilities, including core bioanalysis, toxicology, pathology and clinical laboratory instruments, as well as neuro, cardiovascular and behavioral assessment equipment for animal studies. With close to half of the allocated proceeds, we plan to complete the initial build-out of such GLP facilities and animal housing and husbandry equipment in 2026, to ensure compliant delivery of existing and expected projects and to establish a reasonably comprehensive nonclinical evaluation capability. From 2027 to 2030, we would apply the rest of the allocated proceeds to optimize and

upgrade these platforms in line with business growth and technology advances. Approximately [2.0]%, or HK$[**REDACTED**] million, would be used for laboratory technology improvement, laboratory furnitures and related renovation.

(c) Approximately [12.0]%, or HK$[**REDACTED**] million, will be used property leasing and associated utility expenditures for the project, including (1) approximately [5.1]%, or HK$[**REDACTED**] million, for lease expenses, which would be allocated over time in line with the lease payment schedules; and (2) approximately [6.9]%, or HK$[**REDACTED**] million, for utility expenses, which would be allocated based on the actual usage of equipment and the consumption of relevant resources.

(ii) Approximately [20.0]%, or HK$[**REDACTED**] million, will be allocated to continue expanding and strengthening our NAMs platform and building collaborations with leading academic institutions and innovative pharmaceutical companies. We aim to continuously enhance the platform's technical reliability and standardization, ultimately improving the efficiency and quality of nonclinical studies.

(a) Approximately [5.0]%, or HK$[**REDACTED**] million, will be used for the procurement of related equipment and consumables such as fully automated organoid culture and detection, multi-agent system, live-cell imaging and AI analysis system. We plan to apply the majority of the allocated proceeds from 206 to 2028 to complete initial build-out of the platform and apply the remaining portion for upgrade and expansion in 2029 and 2030 in line with business growth.

(b) Approximately [5.0]%, or HK$[**REDACTED**] million, will be used for the recruitment of over 50 professionals (with around 10 to 15 new hires in each of 2026 and 2027 and round 5 to 10 in each of 2028, 2029 and 2030) such as data processing specialists, translational scientists with expertise in novel drug development and regulatory affairs and experienced technical professionals.

(c) Approximately [5.0]%, or HK$[**REDACTED**] million, will be used for R&D collaborations. We plan to establish in-depth collaborations with leading academic institutions and specialized bioscience research centers to jointly develop and validate advanced biomedical technologies such as 3D organoids, organ-on-chip and multi-organ chip systems, while focusing on practical applications in key disease areas such as cardiology, neurology and hepatology. From 2026 to 2030, we plan to phase in these collaborations, beginning with work on relevant cell and organoid models, progressing to model co-development, test material and reagent collection, assay implementation and preparation for regulatory submissions, and ultimately leading to retrospective and prospective validation studies to support drug evaluation and obtain regulatory recognition. We expect to deploy a larger portion of the proceeds in the earlier years, with the balance applied in the later years as we expand collaborative projects, increase validation activities and pursue broader regulatory acceptance.

(d) Approximately [5.0]%, or HK$[**REDACTED**] million, will be used for leasing additional research space for multiple specialized laboratories with complementary functions, such as fully automated organoid culture and testing laboratory, electrophysiology laboratory and molecular laboratory.

(iii) Approximately [10.0]%, or HK$[**REDACTED**] million, will be allocated to establish a translational science and innovation center, further reinforcing our technical expertise and innovative capabilities. This center will be operated by a biology team comprising experienced specialists. Leveraging advanced analytical tools, the team will perform in-depth analysis and interpretation of nonclinical data to generate high-confidence translational insights, converting nonclinical findings into concrete recommendations on clinical trial design.

The center will also conduct targeted translational precision proof-of-concept studies, similar to services we have previously provided for certain oligonucleotide therapeutics. Informed by efficacy or safety signals identified in ongoing or completed clinical studies, the team will design and conduct tailored, mechanism-driven nonclinical studies to explore and substantiate potential risk-mitigation or efficacy-enhancement strategies. The resulting translational data package is intended to provide a robust scientific basis to refine clinical trial design and inform the overall clinical development strategy.

(a) Approximately [5.5]%, or HK$[**REDACTED**] million, will be used for establishing a high-impact, insights-driven biology team through (i) procuring advanced bioinformatics software to support data-driven analysis and inform decision-making (with proceed allocated consistently over the period from 2026 to 2030, subject to adjustments based on procurement needs); and (ii) recruiting related personnel (with around five to seven new hires in aggregate from 2026 to 2028 and around 10 new hires in each of 2029 and 2030), including translational toxicologists with proven industry expertise, clinical pharmacologists experienced in real-world data interpretation and application, and translational biologists skilled in biomarker development and validation.

(b) Approximately [4.5]%, or HK$[**REDACTED**] million, will be used for enhancing nonclinical, precision proof-of-concept studies that directly address evolving clinical needs, including (i) developing and validating *in vivo* and *in vitro* disease models, as well as establishing integrated assay platforms, such as animal facilities, animal procurement, *in vitro* experiment systems and sophisticated analytical instrument (with the majority of the allocated proceeds planned for initial build-out in 2026 and 2027, and the remaining portion reserved for further upgrades in later years); and (ii) recruiting related personnel (with around ten new hires in total from 2026 to 2030), including experienced model development specialists, senior research scientists with strong cross-disciplinary understanding of clinical requirements and disease mechanisms, and senior project managers capable of leading complex, multi-stage programs.

(iv) Approximately [15.0]%, or HK$[**REDACTED**] million, will be used to establish an international business development (BD) team and employee development framework. We have established a Hong Kong subsidiary and plan to recruit experienced international BD professionals and implement a robust employee training program to enhance our global BD capabilities and deepen strategic client engagement. Through our international BD team, we plan to conduct in-person visits and meetings with existing and prospective overseas clients and execute targeted marketing initiatives, which may include (i) digital campaigns on specialized platforms to build brand awareness, (ii) participation in major industry conferences and events to strengthen our scientific and industry profile and (iii) collaboration

with upstream and downstream partners to better identify and address client needs and generate new business opportunities. We will primarily focus on markets in North America, Europe, Japan and South Korea.

(a) Approximately [10.5]%, or HK$[**REDACTED**] million, will be used to recruit around 20 international BD specialists over the period from 2026 to 2028.

(b) Approximately [4.5]%, or HK$[**REDACTED**] million, will be used for BD training and employee training programs, market outreach activities and leasing for overseas offices over the period from 2026 to 2030.

(v) Approximately [15.0]%, or HK$[**REDACTED**] million, will be used for potential acquisition of suitable CRO companies and related assets in China and overseas.

When evaluating suitable acquisition targets, we take into consideration a variety of factors, including (i) the target's core business activities, which should achieve strategic synergies with our existing operations and expand our integrated service scope (for example, high-quality nonclinical service providers with strong capabilities in novel therapeutic modalities); (ii) geographic advantages, particularly locations that align with our domestic and international footprint and facilitate operational synergies (for example, entities with established presence in North America, Europe or other key overseas markets); (iii) the target's headcount and GLP certifications (by the NMPA, OECD or FDA); (iv) the diversity and growth potential of its client base, with preference given to those serving high-quality MNCs or biotech companies; (v) advanced capabilities in specialized therapeutic areas including ophthalmology, cardiometabolic diseases and CNS diseases; and (vi) a stable historical financial performance and strong prospects for future growth. Based on the criteria listed above, the current market size, the number of existing GLP-certified companies and the business and financial conditions of well-established companies in our focused therapeutic areas, Frost & Sullivan is of the view that there are sufficient potential acquisition targets in the market.

(vi) Approximately [10.0]%, or HK$[**REDACTED**] million, will be used for working capital and general corporate purposes.

In the event that the [**REDACTED**] is set at the [**REDACTED**] or the minimum [**REDACTED**] of the indicative [**REDACTED**] range, the net proceeds of the [**REDACTED**] will increase or decrease by approximately HK$[**REDACTED**] million, respectively. We intend to apply the additional or reduced net proceeds to the above uses on a pro rata basis.

The additional net proceeds that we would receive if the [**REDACTED**] was exercised in full would be HK$[**REDACTED**] million (assuming an [**REDACTED**] of HK$[**REDACTED**] per Share, being the midpoint of the indicative [**REDACTED**] range). We intend to apply the additional net proceeds to the above uses on a pro rata basis.

To the extent that the net proceeds of the [**REDACTED**] are not immediately used for the above purposes or if we are unable to effect any part of our future development plans as intended, we may hold such funds in short-term interest-bearing accounts at licensed commercial banks and/or other authorized financial institutions (as defined under the Securities and Futures Ordinance or applicable laws and regulations in other jurisdictions. We will make an appropriate announcement if there is any change to the above proposed use of proceeds.